Literature DB >> 16192601

Population-based analysis of prognostic factors and survival in familial melanoma.

Scott R Florell1, Kenneth M Boucher, Gilda Garibotti, John Astle, Richard Kerber, Geraldine Mineau, Charles Wiggins, R Dirk Noyes, Alexander Tsodikov, Lisa A Cannon-Albright, John J Zone, Wolfram E Samlowski, Sancy A Leachman.   

Abstract

PURPOSE: Familial melanoma patients are reported to present with thinner melanomas, to be younger at the time of diagnosis, and to have a greater likelihood of developing multiple primary tumors. We sought to determine whether melanomas that occur in a familial setting demonstrate different prognostic and survival statistics relative to sporadic melanoma. PATIENTS AND METHODS: This population-based study used the Utah Cancer Registry and Utah Population Database to objectively evaluate prognostic and survival statistics of the familial melanoma population. From 1973 to 1999, there were 7,785 cases of invasive melanoma identified through the Utah Cancer Registry. These were linked to the Utah Population Database, resulting in 2,659 subjects with family-history information from which a familiality score could be calculated. Cases scored in the top ninth percentile were assigned as high familial risk, and the remaining 91% were considered low familial risk.
RESULTS: Multivariate logistic-regression analysis found no association between sex, Breslow depth, Clark level, or survival and the familial status. Age at first diagnosis of invasive melanoma was slightly lower in the high-familial-risk group (57 v 60 years; P = .03). High-familial-risk subjects had more melanomas diagnosed at age 30 or younger (12% v 6%; P < .001). A significant difference in the overall number of individuals with two or more primary malignant melanomas was not detected among the groups (P = .2).
CONCLUSION: These data suggest that melanomas occurring in the context of an underlying inherited susceptibility do not have a significantly different biologic behavior.

Entities:  

Mesh:

Year:  2005        PMID: 16192601     DOI: 10.1200/JCO.2005.11.999

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

2.  Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database.

Authors:  Kyriaki Antonopoulou; Irene Stefanaki; Christina M Lill; Foteini Chatzinasiou; Katerina P Kypreou; Fani Karagianni; Emmanouil Athanasiadis; George M Spyrou; John P A Ioannidis; Lars Bertram; Evangelos Evangelou; Alexander J Stratigos
Journal:  J Invest Dermatol       Date:  2014-11-19       Impact factor: 8.551

Review 3.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

Review 4.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

5.  Impact of melanoma genetic test reporting on perceived control over melanoma prevention.

Authors:  Lisa G Aspinwall; Tammy K Stump; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Behav Med       Date:  2015-03-31

6.  Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Authors:  Nicholas J Taylor; Nandita Mitra; Lu Qian; Marie-Françoise Avril; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Alisa M Goldstein; Thais C Grazziotin; Nelleke A Gruis; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Elizabeth A Holland; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia L Pritchard; Susana Puig; Helen Schmid; Nienke van der Stoep; Margaret A Tucker; Karin A W Wadt; Xiaohong R Yang; Julia A Newton-Bishop; Peter A Kanetsky
Journal:  J Am Acad Dermatol       Date:  2019-02-05       Impact factor: 11.527

7.  Melanoma risk assessment based on relatives' age at diagnosis.

Authors:  Yelena P Wu; Wendy Kohlmann; Karen Curtin; Zhe Yu; Heidi A Hanson; Mia Hashibe; Bridget G Parsons; Jathine Wong; Joshua D Schiffman; Douglas Grossman; Sancy A Leachman
Journal:  Cancer Causes Control       Date:  2017-12-14       Impact factor: 2.506

Review 8.  Hereditary genodermatoses with cancer predisposition.

Authors:  Meg R Gerstenblith; Alisa M Goldstein; Margaret A Tucker
Journal:  Hematol Oncol Clin North Am       Date:  2010-10       Impact factor: 3.722

9.  Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.

Authors:  Michael R Sargen; Donato Calista; David E Elder; Daniela Massi; Emily Y Chu; Míriam Potrony; Ruth M Pfeiffer; Cristina Carrera; Paula Aguilera; Llucia Alos; Susana Puig; Rosalie Elenitsas; Xiaohong R Yang; Margaret A Tucker; Maria Teresa Landi; Alisa M Goldstein
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

10.  Genetic counseling in melanoma.

Authors:  Celia Badenas; Paula Aguilera; Joan A Puig-Butillé; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Dermatol Ther       Date:  2012 Sep-Oct       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.